Introduction {#Sec1}
============

Due to its reduced density, Helium/Oxygen (He/O~2~) reduces the work of breathing, intrinsic PEEP and hypercapnia more than Air/O~2~ during non-invasive ventilation (NIV) in COPD exacerbations \[[@CR1], [@CR1]\]. Two prospective, randomized multicenter trials were inconclusive in showing a benefit of He/O~2~ NIV on outcome (intubation, mortality, length of stay (LOS) in ICU) but were potentially underpowered \[[@CR1], [@CR1]\].

Objectives {#Sec2}
==========

To evaluate whether 72-hr continuous He/O~2~ during both spontaneous breathing and NIV is superior to Air/O~2~ in reducing NIV failure (intubation or mortality during ICU stay) in severe hypercapnic COPD exacerbations. Secondary outcomes included physiological parameters, duration of ventilation, ICU and hospital LOS, 6-month recurrence and rehospitalization rates.

Methods {#Sec3}
=======

Prospective, randomized multicenter (16 centers in 6 countries) trial, comparing the two gas mixtures for a maximum of 72 hours. Hypothesis was that He/O~2~ would reduce intubation rate from 25% to 15%, resulting in a total sample size of 670 patients. Spontaneous breathing and NIV were applied with specific devices for He/O~2~. Same ventilator was used in both arms.

Results {#Sec4}
=======

The trial was stopped prematurely for futility (low intubation rate reported by the adjudication committee). 445 patients were included (mean ± SD 68 ± 11 yrs; M:F 69:31%; BMI 26 ± 6 kg/m^2^; SAPS 3 49 ± 8; Resp rate (RR) 29 ± 6/min - PaO~2~ 75 ± 36 mmHg; PaCO~2~ 69 ± 16 mmHg; pH 7.30 ± 0.06 - intention-to-treat data set), with no baseline difference between He/O~2~ vs. Air/O~2~. The primary outcome was negative (Figure [1](#Fig1){ref-type="fig"}) and baseline pH was the only significant predictor of NIV failure. NIV failure occurred in the first 72 hours (while receiving the study treatment) in 58% of failures with He/O~2~ and 84% with Air/O~2~ (p = 0.97). RR (Figure [2](#Fig2){ref-type="fig"}), pH, PaCO~2~ and encephalopathy improved faster and with greater magnitude with He/O~2~Figure 1Figure 2

Conclusions {#Sec5}
===========

NIV failure rate was not reduced by He/O~2~ administered during NIV and spontaneous breathing for up to 72 hrs. Failure rate was low in both groups, reflecting the current efficacy of NIV in decompensated COPD. However, He/O~2~ led to improved physiological response, thus confirming previous results, and a shorter duration of invasive ventilation and ICU stay in patients with NIV failure.
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